LumeNXT recently announced Marc Beer as the newly appointed Chairman of the Board. The company is privately-held and specializes in the development of a surgical illumination product line designed to enhance surgeries that have a minimally invasive approach. The focuses on pioneering the use of LED illumination for intracavity purposes, the company’s illumination platform being used as a mechanism in order to improve safety, efficiency and precision via enhanced visualization.
Surgeons who have used targeted illumination noted that this technology is able to enhance flexibility, precision and visualization during operations. The illumination platform offered by LumeNXT is used as a heat reduction mechanism, this being designed to improve low-cost disposable option, as well as surgical precision, as well as safety.
Marc Beer talked about his new role in the company, noting that he is proud to be working with LumeNXT’s group of surgeons and engineers, describing them as dedicated and accomplished, as they advanced the field of surgical illumination by using the company’s technology. The new Chairman of the Board also stated that he considers that the platform’s importance will increase, given that more surgeries get performed using minimally invasive approaches.
The company’s co-founder, Paul Rhyne, also commented on the appointment of Marc Beer as the Chairman of the Board, stating that he demonstrated high levels of success within the startup companies that he has guided through phases of growth. The co-founder went on to highlight the fact that Beer has experience in starting and guiding companies to profitability, noting that his experience is highly valued at LumeNXT, as the company is growing.
The new Chairman of the Board brings over 25 years of experience in development and commercialization areas in sectors such as pharmaceuticals, diagnostics, devices, and biotechnology. Besides his new role at LumeNXT, Marc Beer is also the co-founder and the Chief Executive Officer of Renovia, Inc. The company was founded in August of 2016, and specializes in discovering and delivering digital therapeutic and diagnostic devices to those suffering from pelvic floor disorders. Throughout his long career, beer held a number of roles in companies that are part of the healthcare sector.
In 2000, Beer took on the role of Founding Chief Executive Officer at ViaCell – a biotech company that was focusing on umbilical cord blood stem cells. His role lasted seven years, leading the company from its inception through a phase of rapid growth. Under his leadership, ViaCell had 300 employees, and went public in 2005. The company ended up being acquired afterwards by PerkinElmer, in 2007. Beer also played a role at Genzyme in the sales and marketing department, was part of the diagnostic divisions at Abbott Laboratories, and was a member of the Mass Life Science Board at the Commonwealth of Massachusetts. Learn more: https://www.crunchbase.com/person/marc-beer